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Antiarrhythmic treatment has recently made remarkable progress. In addition to the
conventional pharmacotherapy, nonpharmacologic treatment has become popular and has
achieved better therapeutic eﬀects than before. Under these circumstances, pharmacother-
apy has still been the mainstay of antiarrhythmic treatment because its convenience and
high eﬃcacy. However, phamacotherapy of arrhythmias actually does not achieve suﬃcient
therapeutic eﬀect in many cases, and physicians often encounter several diﬃculties in
antiarrhytmic treatment. This is because arrhythmias have some characteristics including
the following: (a) arrhythmias have diﬀerent clinical signiﬁcances according to whether
they are or are not accompanied by organic cardiac disorder, (b) arrhythmias are not always
present, even the same type of arrhythmias appears in diﬀerent manners or at diﬀerent
frequencies, and thus there is circadian variation or day to day variation, (c) severity of
arrhythmias and subjective symptoms do not always conform. Because of these character-
istics of arrhythmias, special care is required for the judgement of necessity for treatment,
selection of a drug, establishment of a treatment goal, valuation of therapeutic eﬀects and
assessment of prognosis. When it was determined that the condition required treatment, a
drug is selected on the basis of the relation between the mechanism of the onset and
perpetuation of arrhythmias and the electrophamacologic eﬀects of the drug. After a proper
drug is selected, establishment of treatment goal is the problem. The ideal goal of
antiarrhythmic treatment is to resolve arrhythmias and prevent recurrence, and thus to
improve prognosis. It is not always easy, however, to achieve this goal by pharmacotherapy
alone. One of the factors that make pharmacotherapy of arrhythmias diﬃcult is
proarrhythmic eﬀect of drug used for treatment. For example, if the dose of an
antiarrhythmic drug is increased based on the judgement that the normal dose is not
eﬀective enough or if a drug is administered carelessly for a long period, it will induce
severe arrhythmias that may result in serious outcomes. In such cases, the treatment goal
should be reviewed, but there are no standards for review. Physicians have to review the
patient’s clinical condition to establish the second-best treatment goal. In addition, long
term use of a drug has unsolved problems. Chronic administration of a drug without a
speciﬁc aim will cause psychological and/or economic burden on patients or adverse
reactions to the drug. If the drug is discontinued without discretion because of such
problems, another problem, such as recurrence of arrhythmias, may occur and physicians
may often have a diﬃculty to cope with it. At present, there is no consensus as to when to
consider discontinuation of a drug. There is also a possibility that, while a drug is
administered for a long period, myocardial damage may progress during the course and
thereby changing the histological and electrical based of arrhythmia. In that case, there is no
assurance that the drug that was eﬀective at the start of treatment continues to be eﬀective
for long period. It remains unknown at present whether the adequate eﬃcacy will continue.
Physicians who are involved in the treatment of arrhythmia should be fully aware of these
problems. I hope that progress of understandings in this ﬁeld will solve the above-
mentioned problems underlying the pharmacotherapy of arrhythmias and lead to further
advancement in pharmacotherapy of arrhythmia.
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